Data from A Comprehensive Expression Analysis of Cancer Testis Antigens in Head and Neck Squamous Cell Carcinoma Revels <i>MAGEA3/6</i> as a Marker for Recurrence

Abstract

<div>Abstract<p>Despite significant advances in the treatment of head and neck squamous cell carcinoma (HNSCC), the survival rate has not changed in the last decades. Therefore, the development of novel therapeutic strategies is pursued. Cancer–testis antigens (CTA) are strong immunogenic proteins with a tumor-restricted expression pattern, and are considered ideal targets for tumor-specific immunotherapeutic approaches. In this study, using an <i>in silico</i> approach, we selected, among 139 previously described CTA, candidates to be evaluated in 89 HNSCC and 20 normal mucosa samples. <i>SPANX-CD</i> (71.9%), <i>MAGEB2</i> (44.9%), <i>MAGEA1</i> (44.9%), <i>MAGEB6</i> (32.6%), and <i>CXORF48</i> (27.0%) were found frequently expressed in HNSCC, and over 85% of the tumors expressed at least one of these five CTAs. The mRNA positivity of <i>CXORF48</i>, <i>MAGEB6</i>, and <i>CRISP2</i> presented significant associations with recognized clinical features for poor outcome. Furthermore, <i>MAGEA3</i>/<i>6</i> positivity was associated with significantly better disease-free survival (DFS, <i>P</i> = 0.014), and the expression of this antigen was shown to be an independent prognostic factor for tumor recurrence. In conclusion, one of five selected CTAs is expressed in at least 85% of the HNSCCs, suggesting a possible usage as target for immunotherapeutic approaches, and the mRNA-positivity for <i>MAGEA3</i>/<i>6</i> is shown to be an independent marker for DFS. <i>Mol Cancer Ther; 14(3); 828–34. ©2015 AACR</i>.</p></div>